Precision Medicine in Oncology®
Latest News
Advertisement
Latest Videos
CME Content
Advertisement
More News
Dr. Giorgio V. Scagliotti from the University of Turin Discusses the Future of Lung Cancer Therapy
Dr. Hope S. Rugo from University of California, San Francisco on Anti-Angiogenesis Therapy Response Predictors
Dr. Matthew J. Ellis from Washington University on Measuring Endocrine Therapy Efficacy With Ki67
Johan Lennartsson's research focuses on platelet-derived growth factor receptor (PDGFR) and mitogen-activated protein kinase (MAPK) signaling in normal physiology and cancer.
The breadth of the stem cell factor (SCF)/ KIT signaling pathway oncogenic functions and potential role as a therapeutic target are just now becoming clear.
Dr. Debu Tripathy from the USC Norris Cancer Center on Connecting Markers to Clinical Outcomes
Established in 1970 as a small clinic for cancer patients, the Georgetown Lombardi Comprehensive Cancer Center was named for football coach Vince Lombardi, who was treated for cancer at Georgetown University Hospital.
Dr. Matthew J. Ellis from Washington University Discusses Ki67 as a Treatment Monitoring Biomarker
Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on the Future of Breast Cancer Biomarkers
Dr. Matthew J. Ellis from Washington University Discusses the Future of the PI3-Kinase Pathway
Dr. Matthew Ellis from Washington University Discusses the Cell-Proliferation Marker Ki67
It's hard to tell which moves more quickly: Edith Perez's feet, or her mind.
Dr. Karen Reckamp City of Hope cancer center on Current Heat Shock Protein Clinical Trials
Dr. Debu Tripathy from UC Norris Cancer Center Discusses HER2 Targeted Therapies
Biological markers that help clinicians choose which treatment options to pursue for particular patients are attracting increased research interest.
Dr. Debu Tripathy from USC Norris Cancer Center on Completing New Assays After Recurrence
Biomarkers offer great potential for improving management of cancer at every point from screening and detection, to diagnosis, staging, prognosis, and the assessment of treatment response.
Dr. Antonio C. Wolff from Sidney Kimmel Comprehensive Cancer Center Discusses the Importance of HER2 Testing
Dr. Debu Tripathy from USC Norris Cancer Center on the Oncotype DX Assay Recurrence Score
Dr. Debu Tripathy from USC Norris Cancer Center Discusses Breast Cancer Gene Profiling
Dr. Debu Tripathy from the USC Norris Comphrensive Cancer Center Discusses Breast Cancer Biomarkers
Amid a continuing emphasis on targeted therapies, pharmaceutical companies have approximately 300 drugs in phase II or later-stage development for cancer treatment.
Dr. Mark G. Kris from Memorial Sloan-Kettering Cancer Center Discusses Available Targeted Therapies
As personalized medicine occupies a growing role in the pharmaceutical pipeline, major companies are changing their research and development paradigms.
The oncology community is quite conversant with the clinical utility of prognostic tumor markers.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Therapy Designation to 64Cu-SAR-bisPSMA for PSMA PET in Biochemically Recurrent Prostate Cancer
2
Detalimogene Responses Improve With Longer Follow-Up in BCG-Unresponsive NMIBC Ahead of BLA Submission
3
Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models
4
Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer
5